Although blocking ALOX5 with zileuton decreases the survival of CML LSCs in mice, targeting ALOX5 is unlikely to be successful due to the low expression of ALOX5 in humans [33]. The gene discussed is ALOX5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.